Clinical Trial Update: Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study of polatuzumab vedotin with the R-GDP regimen in relapsed/refractory diffuse large B-cell lymphoma was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Gemcitabine (Gemzar) (gemcitabine)
• Polatuzumab Vedotin (Polivy) (polatuzumab vedotin)
• Rituximab (Rituxan) (rituximab)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Diffuse Large B-cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2026-04-16